TBPH

Q: What is the price of Theravance Biopharma (TBPH) today?

A cotação de Theravance Biopharma (TBPH) hoje está em $ 16.22, com uma variação de The stock began the year trading around $ 18.71 and is currently priced at $ 16.22. negociando na casa dos $ 18.71 e hoje está em $ 16.22. Acompanhe o and track broader market trends directly on the platform.

Q: When does Theravance Biopharma (TBPH) pay dividends?

Theravance Biopharma (TBPH) did not pay dividends over the past year.

Q: Is Theravance Biopharma (TBPH) a good investment?

Atualmente, Theravance Biopharma (TBPH) está cotada a $ 16.22, com um P/L de 7.57, This represents a -11% premium compared to its historical average P/E. uma variação de 77.46 em sua cotação e distribuiu $ 0.00 em dividendos, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 77.46%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

Theravance Biopharma Inc.

Price

$ 16.22

return (12m)

77.46%

p/e

7.57

p/bv

2.99

DIVIDEND YIELD

0.00%

TBPH price

TBPH

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment TBPH

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-2.52%

3 months

-16.95%

1 year

77.46%

2 years

64.67%

5 years

-13.35%

10 years

0.00%

Fundamentals TBPH

review the fundamentals of Theravance Biopharma shares

P/E

7.57

Sector: -1.87 Industry: -7.03

P/S (PSR)

7.90

Sector: 2.02 Industry: 3.21

P/BV

2.99

Sector: 2.13 Industry: 2.02

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

24.25%

Sector: -25.73% Industry: -47.63%

ROE

39.42%

Sector: -29.29% Industry: -41.43%

ROIC

-17.13%

Sector: -428.36% Industry: -515.65%

NET MARGIN

100.00%

Sector: -27.90% Industry: -31.82%

GROSS MARGIN

100.00%

Sector: 45.02% Industry: 45.03%

OPERATING MARGIN

4.53%

Sector: -22.78% Industry: -27.21%

EV/EBITDA

6.14

Sector: -0.17 Industry: -2.48

EV/EBIT

6.25

Sector: -1.98 Industry: -6.01

PRICE-TO-ASSETS

1.84

Sector: 1.15 Industry: 1.30

BVPS

5.70

Sector: 3.73 Industry: 2.08

EPS

2.25

Sector: -0.83 Industry: -1.27

EQUITY-TO-ASSETS RATIO

0.62

Sector: 0.43 Industry: 0.49

LIABILITIES / ASSETS

0.38

Sector: 0.47 Industry: 0.43

CAGR REVENUE 5 YEARS

14.69%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Theravance Biopharma ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 16.22

Fair Value

$ 0.00

Upside/Downside Return potential.

4.73%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals TBPH

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
LLY	33.59	27.21	81.01%	0.66%	$ 848.86 B	34.98%
ISRG	53.63	9.08	16.93%	0.00%	$ 159.77 B	28.15%
TMO	25.26	3.32	13.15%	0.38%	$ 172.98 B	15.15%
SNY	11.59	1.26	10.86%	5.11%	$ 105.72 B	18.68%
NVS	20.60	7.16	34.77%	2.12%	$ 278.77 B	23.92%
ABT	25.14	0.00	0.00%	2.64%	$ 157.79 B	13.91%
MDT	21.18	1.99	9.38%	3.73%	$ 97.70 B	13.00%
GSK	12.93	4.37	33.77%	3.48%	$ 101.42 B	17.79%
CVS	39.31	1.48	3.78%	2.94%	$ 115.27 B	0.72%
BSX	22.46	0.00	0.00%	0.00%	$ 80.09 B	17.29%
TMDX	13.42	4.67	34.80%	0.00%	$ 2.31 B	27.04%
HCA	14.35	-32.73	-228.14%	0.68%	$ 97.48 B	8.89%
IDXX	40.91	28.80	70.38%	0.00%	$ 44.81 B	24.63%
RMD	19.73	4.62	23.41%	1.13%	$ 29.98 B	27.44%
DHR	32.85	2.29	6.97%	0.79%	$ 121.18 B	14.89%
INMD	10.09	1.33	13.18%	0.00%	$ 879.48 M	23.27%
PHG	22.93	1.96	8.56%	3.26%	$ 25.90 B	5.50%
SYK	32.76	4.76	14.52%	1.21%	$ 109.34 B	13.21%
FMS	11.00	0.74	6.71%	3.57%	$ 12.12 B	4.89%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*The value considers the reinvestment of dividends.

TBPH Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Theravance Biopharma

Theravance Biopharma Inc.

Average Investor10 user rating

4.0 (2 people)

United States

13 years

Founded: 2013

2014

Time since IPO - 12 years

359

Employees

Theravance Biopharma Inc. (United States) is listed on the Nasdaq and has a market capitalization of $867.51 Millions, with shareholders equity totaling $290.59 Millions.

The company employs approximately 359 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Theravance Biopharma Inc. reported $109.78 Millions in revenue, generating net income of $114.55 Millions.

Key financial metrics include a P/E ratio of 7.57, a price-to-book (P/B) ratio of 2.99, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TBPH.

Market cap

$ 867.51 Millions

Net worth

$ 290.59 Millions

$ 290,590,000.00

Assets

$ 472.31 Millions

$ 472,310,000.00

Total Shares Outstanding

51.00 Millions

51,000,000

Average Daily Trading Volume

$ 646.88 Thousand

$ 646,879.02

Sector

Health

Industry

Pharmaceutical Products

TBPH

TBPH revenue and profits

Financial Results TBPH

DRAG THE FRAME TO SEE MORE DATA

TBPH cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

CVS - CVS Health

$ 95.89 58,96% (12M)

P/E

39.31

2.94%

ROE

3.78%

P/BV

1.48

CI - Cigna

$ 285.27 --8,74% (12M)

P/E

10.52

2.11%

ROE

16.97%

P/BV

1.79

CNC - Centene

$ 58.27 --5,68% (12M)

P/E

-4.27

0.00%

ROE

-29.93%

P/BV

1.28

HUM - Humana

$ 305.12 30,67% (12M)

P/E

29.20

1.29%

ROE

6.06%

P/BV

1.77

LLY - Eli Lilly

$ 1,004.92 34,30% (12M)

P/E

33.59

0.66%

ROE

81.01%

P/BV

27.21

HCA - HCA Healthcare

$ 423.00 10,09% (12M)

P/E

14.35

0.68%

ROE

-228.14%

P/BV

-32.73

NVS - Novartis

$ 148.08 37,77% (12M)

P/E

20.60

2.12%

ROE

34.77%

P/BV

7.16

ABT - Abbott

$ 84.47 --36,06% (12M)

P/E

25.14

2.64%

ROE

0.00%

P/BV

0.00